Multicenter Analytical Validation of Aβ40 Immunoassays

Abstract : Before implementation in clinical practice, biomarker assays need to be thoroughly analytically validated. There is currently a strong interest in implementation of the ratio of amyloid-β peptide 1-42 and 1-40 (Aβ42/Aβ40) in clinical routine. Therefore, in this study, we compared the analytical performance of six assays detecting Aβ40 in cerebrospinal fluid (CSF) in six laboratories according to a recently standard operating procedure (SOP) developed for implementation of ELISA assays for clinical routine.
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01758275
Contributor : Anthony Herrada <>
Submitted on : Wednesday, April 4, 2018 - 12:53:23 PM
Last modification on : Wednesday, November 20, 2019 - 3:22:11 AM

Links full text

Identifiers

Citation

Linda van Waalwijk van Doorn, Luka Kulic, Marleen Koel-Simmelink, H. Bea Kuiperij, Alexandra Versleijen, et al.. Multicenter Analytical Validation of Aβ40 Immunoassays. Frontiers in Neurology, Frontiers, 2017, 8, pp.310. ⟨10.3389/fneur.2017.00310⟩. ⟨hal-01758275⟩

Share

Metrics

Record views

111